2015 European Cancer Congress
M. Catherine Pietanza, MD, on A Promising New Agent for SCLC
M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell...
Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial
Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for l...
Martine Frouws, MSc, PhD, on Postdiagnosis Aspirin and Improved Survival in All GI Cancers
Martine Frouws, MD, PhD Candidate, of Leiden University Medical Centre discusses her study, which showed a significant increase in overall survival among patients with GI cancers who took aspirin comp...
Federico Cappuzzo, MD, and Tony Mok, MD, on Managing EGFR Resistance in Lung Cancer
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resi...
Michel Ducreux, MD, PhD, on Results of the Phase II COLO 001 Clinical Trial
Michel Ducreux, MD, PhD, of the Institut Gustave Roussy, discusses the efficacy and safety in this study of nab-paclitaxel in patients with previously treated metastatic colorectal cancer (Abstract 21...
Jean-Yves Douillard, MD, PhD, on New Perspectives in Small Cell Lung Cancer
Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.
Christoph Zielinski, MD: Highlights of 2015 European Cancer Congress
As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 C...
Jonathan E. Rosenberg, MD, on Results of the IMvigor 210 Study on Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses this pivotal study of an investigational immunotherapy that has shown increased and durable responses, with a relatively...
Mary K. Gospodarowicz, MD, on Challenges in Cancer Control
Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital radiation treatment ...
Cora N. Sternberg, MD, on New Targets in Renal Cell Carcinoma
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
Clifford A. Hudis, MD, on Obesity, Inflammation, and Cancer
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.
Priscilla K. Brastianos, MD, on Genetic Screening of Brain Metastases
Priscilla K. Brastianos, MD, of Massachusetts General Hospital, discusses genomic characterization of brain metastases and paired primary tumors, which could reveal potential therapeutic targets (Abst...
Clifford A. Hudis, MD, on Results of the TAILORx Clinical Trial
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (...
Frederic Amant, MD, PhD, on Cancer and Pregnancy
Frederic Amant, MD, PhD, of the Katholieke Universiteit Leuven, discusses the important decisions that must be made when a woman is diagnosed with cancer while pregnant: Should treatment be delayed or...
Looking Ahead With the New ECCO President: Peter L. J. Naredi, MD, PhD
Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer t...
Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib
Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of ...
A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer
A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of men with advanced pr...
Matti S. Aapro, MD, on Geriatric Oncology: A Multidisciplinary Approach for Positive Outcomes
Matti S. Aapro, MD, of IMO Clinique de Genolier, offered a case presentation and a cross-disciplinary approach to finding the best way to effect a cure with minimal impact on quality of life.
Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy
Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstr...
Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study
Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
Michael Pfreundschuh, MD, on Treating Lymphoid Malignancies in Children and Adults With the Same Protocols
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adu...
Ignacio Melero, MD, PhD, on Developing and Implementing New Immunotherapies
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.
Jean-Charles Soria, MD, PhD, on Results of the KEYNOTE 001 Clinical Trial
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).
Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Martine J. Piccart-Gebhart, MD, PhD, on Reducing the Cost and Increasing Access to Cancer Drugs
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-l...
Rolf A. Stahel, MD, on Results From the BELIEF Trial
Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation...
Lisa Carey, MD, on Molecular Screening for Breast Cancer
Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
Robert J. Motzer, MD, on Phase III Results of CheckMate 025 Nivolumab vs Everolimus in Advanced RCC
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic rena...
Martine J. Piccart-Gebhart, MD, PhD, on New Frontiers in Imaging
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.
Milena Sant, MD, on The Latest Findings From the EUROCARE 5 Study
Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).
Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to ev...
